Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.55 |
| ▸ | NPY4R | P50391 | 4/20 | 0.55 |
| ▸ | NPY1R | P25929 | 3/20 | 0.55 |
| ▸ | NPY2R | P49146 | 3/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.49 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184346 | 0.97 | NPY4R (0.56) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29403649 | 0.94 | NPY4R (0.55) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29531366 | 0.94 | NPY4R (0.55) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29530897 | 0.94 | NPY4R (0.55) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29531210 | 0.94 | NPY4R (0.55) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29730544 | 0.93 | NPY4R (0.58) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29531203 | 0.92 | NPY4R (0.57) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29530953 | 0.92 | NPY4R (0.57) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL30865077 | 0.92 | NPY1R (0.55) | BACE1NPY4RNPY1RNPY2RBACE2 | |
| SCHEMBL29496461 | 0.91 | BACE1 (0.57) | BACE1NPY4RNPY1RNPY2RBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230018324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | IAPP, GLP1R, SLC5A1 | BACE1 498/4885NPY4R 329/4885NPY1R 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.